April 28, 2014 / 11:21 AM / 4 years ago

OncoGenex, Teva say prostate cancer drug fails late-stage trial

April 28 (Reuters) - Teva Pharmaceutical Industries Ltd and OncoGenex Pharmaceuticals Inc said their prostate cancer treatment failed to show improvement over standard chemotherapy in a late-stage trial.

The drug, custirsen, in combination with standard chemotherapy, failed to show statistically significant improvement in overall survival in advanced castrate-resistant prostate cancer patients, compared to those who received chemotherapy alone.

OncoGenex’s stock was halted pending the news. (Reporting by Natalie Grover in Bangalore; Editing by Don Sebastian)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below